NRXS Neuraxis, INC Insider Trading

CEO Brian Allen bought 8,060 shares at $1.96 on 2026-04-01; 2 other insiders also bought in the past 14 days

CEO Brian Allen purchased 8,060 shares at $1.96, increasing his holdings by 2.4% to 348,178 shares, in a transaction worth $15,797.60. This purchase occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated or contemporaneous conviction among multiple company stakeholders. The purchase price of $1.96 represents the lower end of the 52-week range ($1.60–$7.62), and the stock has since recovered to $7.25, up 62.6% over 90 days and +23.1% in the past 30 days. However, the company's fundamentals remain challenged: it posted net income of $-2.1M most recently and was unprofitable over its full fiscal year, despite reporting quarterly revenue of $811.4K and 32.9% annual revenue growth. The multi-insider buying pattern near the historical low warrants tracking against near-term company performance.

CFO Timothy Robert Henrichs buys 7,593 shares at $1.96; 2 other insiders bought within 14 days at unprofitable biotech

Henrichs acquired 7,593 shares at $1.96 on 2026-04-01, representing his first position in NRXS, occurring amid a cluster pattern where 2 other insiders also purchased within the past 14 days. The transaction timing coincides with sharp recent price momentum: the stock has risen 23.1% over 30 days and 62.6% over 90 days, now trading at $7.25 versus the $1.96 entry—a 270% gain from the purchase date. However, the company remains fundamentally challenged: it reported a net loss of $-2.1M over its most recent full fiscal year and continues unprofitable, despite 32.9% annual revenue growth. The multi-insider buy cluster warrants analysis of whether these purchases reflect material non-public information about a turnaround inflection, or whether they are responding to the same publicly visible momentum.

CRO/CCO/CPO Carrico buys 667 shares at $1.96; cluster pattern (2 other insiders bought within 14 days) amid 62.6% 90-day surge but $-2.1M net loss.

Carrico Thomas Joeseph, in his role as CRO, CCO, and CPO, purchased 667 shares at $1.96 on 2026-04-01, adding to his holdings of 331.9K shares post-transaction. This purchase occurs within a cluster buy pattern: two other insiders also bought within the past 14 days. The stock has appreciated significantly—up 62.6% over 90 days and 23.1% over 30 days—trading at $7.25 against a 52-week range of $1.60–$7.62. However, context matters: the company generated only $811.4K in quarterly revenue and reported a full-year net loss of $-2.1M despite achieving 32.9% annual revenue growth. The cluster buying pattern combined with strong recent price momentum could suggest insider perception of value, but the company remains unprofitable, and the small transaction size ($1,307.32) relative to Carrico's existing holdings represents only a 0.2% increase in his position.

10% owner Hannasch Brian buys 80,000 shares ($382.8K) at NRX on 2 consecutive days, raising holdings 7.1%

Hannasch Brian executed 2 separate purchases totaling 80,000 shares for $382,800.00 at an average price of $4.78, increasing his stake from 1,131,522 to 1,211,522 shares. The company generated $811,414.00 in latest quarterly revenue but posted a net loss of $-2,122,796.00 and remains unprofitable on a full-year basis, despite annual revenue growth of +9.2%. His cross-ticker track record shows 3 prior buys with an average 90-day return of +3.8%, though his 2 prior purchases at NRX (July 2025 and April 2025) remain too recent to have measurable 90-day outcomes. The consecutive-day execution and 7.1% increase in holdings suggest sustained conviction in the position, though the timing relative to longer-term share price performance is not yet determinable.

Director Aharon Gil buys 286,138 shares of Neuraxis (NRXS) at $3.52 for $1.0M in first personal stock purchase

Aharon Gil, a director, established an initial position of 286,138 shares valued at $1,007,205.76, representing his first open-market purchase in Neuraxis. The transaction occurred at $3.52 per share, and the stock has since risen to $4.20 (at the high end of its 52-week range of $1.60–$4.20), marking a +30.0% move from his entry. Across his cross-ticker trading history, his prior buy transactions averaged +26.2% 30-day returns and +107.8% 90-day returns with a 100.00% 90-day win rate, establishing a materially favorable execution pattern. However, context warrants caution: Neuraxis generated quarterly revenue of only $811,414.00, posted a full-year net income of $-2,122,796.00, and carries a $44,741,810.40 market cap—a company with negative profitability and limited revenue scale. The entry timing relative to current price at the highs, combined with the company's deeply unprofitable fundamentals, presents a contrasting picture to the insider's historical track record.

10% owner Masimo Corp sold 821,327 shares (821.3K) of NRXS at $2.25 for $1,847,985.75 via 2 transactions

Masimo Corp, a 10% stakeholder in Neuraxis Inc., executed two separate sales totaling 821,327 shares (821.3K shares) for $1,847,985.75 ($1.8M) at $2.25 per share on 2025-07-01. The sale eliminated Masimo's entire shareholding position in NRXS. This transaction occurs against a backdrop of a micro-cap company trading at current prices significantly below its 52-week high (current $2.58 is -35.3% from $3.99 peak) and burning cash, with quarterly revenue of $895,655.00 ($895.7K) against a net loss of $-2,278,684.00 ($-2.3M) and negative full-year net income. While the 90-day price change is +39.5%, the stock has declined -6.9% in 30 days, and the sale was executed at the lower end of recent trading ranges. Note: This filing reflects a derivative conversion; the insider's complete position (including any retained derivative securities per Form 4 Table II) is not yet available in the database and should be verified.

10% owner Hannasch buys 355,556 shares of NRX for $800,001 at $2.25; holdings rise 45.8% to 1.13M shares

Hannasch Brian, a 10% shareholder in Neuraxis, purchased 355,556 shares ($800,001.00 total) on 2025-07-01, increasing his stake by 45.8% from 775,966 shares to 1,131,522 shares. This represents an open-market buy, but context is mixed: while the purchase is material in absolute dollars and percentage terms, the company is fundamentally challenged with net income of $-2,278,684.00 over its most recent full fiscal year despite 9.2% annual revenue growth ($895,655.00 in the latest quarter). His prior same-ticker buy on 2025-04-21 has no measurable 90-day outcome, and his cross-ticker track record shows only 1 prior open-market buy, limiting any pattern evidence. The significance of a major shareholder continuing to accumulate at this valuation deserves monitoring against the company's operating performance.

10% Owner Hannasch Brian buys 18,065 shares of NRX at $1.73; stock accrues unprofitable losses while revenue grows 9.2%.

Hannasch Brian, a 10% owner of Neuraxis, purchased 18,065 shares at $1.73 on 2025-04-21, expanding his holdings by 2.4% to 775,966 shares total. The purchase occurs against mixed fundamentals: the company posted +9.2% annual revenue growth but generated a net loss of $1,755,234.00 over its most recent full fiscal year, with the latest quarter showing revenue of only $666,625.00. The acquisition represents a discretionary open-market purchase, but the broader context—unprofitability persisting despite revenue momentum—leaves material operational questions unresolved. Investors should monitor whether the revenue growth trajectory can eventually lead to profitability, or whether the losses remain structural.